<SEC-DOCUMENT>0001178913-19-002384.txt : 20190923
<SEC-HEADER>0001178913-19-002384.hdr.sgml : 20190923
<ACCEPTANCE-DATETIME>20190923080022
ACCESSION NUMBER:		0001178913-19-002384
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20190923
FILED AS OF DATE:		20190923
DATE AS OF CHANGE:		20190923

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Entera Bio Ltd.
		CENTRAL INDEX KEY:			0001638097
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38556
		FILM NUMBER:		191106271

	BUSINESS ADDRESS:	
		STREET 1:		KIRYAT HADASSAH, MINRAV BUILDING
		STREET 2:		FIFTH FLOOR
		CITY:			JERUSALEM
		STATE:			L3
		ZIP:			9112002
		BUSINESS PHONE:		972-2-532-7151

	MAIL ADDRESS:	
		STREET 1:		KIRYAT HADASSAH, MINRAV BUILDING
		STREET 2:		FIFTH FLOOR
		CITY:			JERUSALEM
		STATE:			L3
		ZIP:			9112002
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk1923496.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using EDGARfilings PROfile 6.3.0.0
         Copyright 1995 - 2019 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div id="DSPFPageHeader">
      <div style="line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">UNITED STATES</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Washington, D.C. 20549</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">FORM 6-K</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">
      <div style="line-height: 1.25; font-weight: bold;">For the month of September 2019</div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25;">Commission file number: 001-38556</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">ENTERA BIO LTD.</div>
    <div style="text-align: center; line-height: 1.25;">(Exact Name of Registrant as Specified in Its Charter)</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Kiryat Hadassah<br>
      Minrav Building &#8211; Fifth Floor</div>
    <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;">Jerusalem, Israel</font><br>
      (Address of principal executive office)</div>
    <div style="text-align: center; line-height: 1.25;">_____________________</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25;">Form 20-F &#9746;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Form 40-F &#9744;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;<font style="font-family: 'Wingdings 2', serif;"></font></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;<font style="font-family: 'Wingdings 2', serif;"></font></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25;"><u>CONTENTS</u></div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;">This report on Form 6-K of the registrant consists of a press release issued by the registrant on September 23, 2019, attached hereto as an exhibit and incorporated by reference herein.</div>
      </div>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;"><u>Exhibit</u></div>
      </div>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z181768f16b814580ab9932237d563007">

          <tr>
            <td style="width: 6%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><a href="exhibit_99-1.htm">Exhibit 99.1:</a></div>
            </td>
            <td style="width: 86.76%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><a href="exhibit_99-1.htm">Press release dated September 23, 2019.</a></div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><u>SIGNATURES</u></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zdf08f44eab76443cbdc0b17e114172a4">

        <tr>
          <td style="width: 49.99%; vertical-align: top;">&#160;</td>
          <td colspan="2" style="vertical-align: top;">
            <div style="line-height: 1.25; font-weight: bold;">ENTERA BIO LTD.</div>
            <div style="line-height: 1.25;">(Registrant)</div>
          </td>
          <td style="width: 12%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 49.99%; vertical-align: top;">&#160;</td>
          <td style="width: 4%; vertical-align: top;">&#160;</td>
          <td style="width: 33.8%; vertical-align: top;">&#160;</td>
          <td style="width: 12%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 49.99%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td style="width: 4%; vertical-align: top; padding-bottom: 2px;">
            <div style="line-height: 1.25;">By:</div>
          </td>
          <td style="width: 33.8%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">/s/Adam Gridley</div>
          </td>
          <td style="width: 12%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 49.99%; vertical-align: top;">&#160;</td>
          <td style="width: 4%; vertical-align: top;">&#160;</td>
          <td style="width: 33.8%; vertical-align: bottom;">
            <div style="line-height: 1.25;">Name: Adam Gridley</div>
          </td>
          <td style="width: 12%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 49.99%; vertical-align: top;">&#160;</td>
          <td style="width: 4%; vertical-align: top;">&#160;</td>
          <td style="width: 33.8%; vertical-align: top;">
            <div style="line-height: 1.25;">Title: Chief Executive Officer</div>
          </td>
          <td style="width: 12%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 49.99%; vertical-align: top;">&#160;</td>
          <td style="width: 4%; vertical-align: top;">&#160;</td>
          <td style="width: 33.8%; vertical-align: top;">&#160;</td>
          <td style="width: 12%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <div style="line-height: 1.25;">Date: September 23, 2019</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit_99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using EDGARfilings PROfile 6.3.0.0
         Copyright 1995 - 2019 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  <div style="text-align: right;"><u><font style="font-weight: bold;">Exhibit 99.1</font></u><br>
  </div>
  <div><br>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" id="zd1ae736f97c04306add6efdb10a389f6" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 49.42%; vertical-align: top; background-color: rgb(255, 255, 255);">
            <div style="line-height: 1.25; font-weight: bold;">Entera Bio Ltd.</div>
            <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
            <div style="line-height: 1.25;">Adam Gridley, CEO</div>
            <div style="line-height: 1.25;">Tel: +972-2-532-7151</div>
            <div style="line-height: 1.25;"><u>adam@enterabio.com</u></div>
          </td>
          <td style="width: 50.58%; vertical-align: top; background-color: rgb(255, 255, 255);">
            <div style="line-height: 1.25; font-weight: bold;">INTERNATIONAL INVESTOR RELATIONS</div>
            <div style="line-height: 1.25;">&#160;</div>
            <div style="line-height: 1.25;">Bob Yedid</div>
            <div style="line-height: 1.25;">LifeSci Advisors</div>
            <div style="line-height: 1.25;">646-597-6989</div>
            <div style="line-height: 1.25;">bob@lifesciadvisors.com</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Entera Bio Reports Positive Results from a Phase 2 PK/PD Study of Oral PTH (1-34) in </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Patients with Hypoparathyroidism</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="zb3c6cd4e3cc64dfeb95c381f1bb5cd23" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">
              <div style="margin-left: 18pt; line-height: 1.25;">&#8226;</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="line-height: 1.25;">Results of a Phase 2 PK/PD study of Oral PTH (1-34) in patients with hypoparathyroidism were presented at the American Society
                for Bone and Mineral Research Annual Meeting</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z3627e67576844a18bb2ce965baec19d8" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">
              <div style="margin-left: 18pt; line-height: 1.25;">&#8226;</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="line-height: 1.25;">Data suggest&#160;favorable pharmacologic and pharmacokinetic profiles of Entera&#8217;s Oral PTH formulation with a flexible oral
                  dosing regimen vs. an injectable form of PTH</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z3e3c6dab062c4394a93bf303cbf06beb" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">
              <div style="margin-left: 18pt; line-height: 1.25;">&#8226;</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="line-height: 1.25;">Data will inform the Phase 2b/Phase 3 clinical development strategy</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">JERUSALEM, Israel &amp; BOSTON, Mass.
        (September 23, 2019)</font> &#8211; Entera Bio Ltd. (NASDAQ: ENTX) today<font style="background-color: #FFFFFF;">&#160;announced the presentation of positive results from its pharmacokinetic (PK) and pharmacodynamic (PD) study in patients with hypoparathyroidism treated with its oral parathyroid hormone (PTH) drug [Oral hPTH(1-34)].&#160; The results were
        presented at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting in Orlando, Florida on September 22, 2019.</font></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;"><font style="background-color: #FFFFFF;">&#8220;Entera&#8217;s previous Phase 2 study
        in hypoparathyroid patients presented in 2016 showed that four times daily (QID) dosing of oral hPTH (1-34) had a positive effect on serum calcium, a reduction in serum phosphate and a reduction in urinary calcium. The goal of this new PK/PD study
        was to compare twice-daily (BID), three times daily (TID) and QID dosing regimens and dose strengths of Entera&#8217;s Oral hPTH (1-34) over a 24-hour period.&#160; The results showed that the largest changes in PD endpoints were found with QID dosing, with
        moderate changes in PD endpoints generally found with&#160; BID and TID dosing.&#160; In addition, the QID dosing decreased urine calcium over 24-hours, which indicates that it may be able to reduce urinary calcium in hypoparathyroid patients with
        hypercalciuria during long-term treatment,&#8221; stated Professor Sofia Ish-Shalom, a principal investigator at the Endocrine Research Center at Lin Medical Center in Haifa, Israel. &#8220;As investigators, we were pleased to see that Oral hPTH (1-34) had a
        positive impact on PD parameters, an increase in serum calcium, a decrease in serum phosphate and an increase in active vitamin D (1,25-dihycroxyvitamin D) synthesis. Importantly, these data again show the ability of Entera&#8217;s oral formulation to
        deliver PTH to the bloodstream at concentrations that produced the anticipated PD effect. Furthermore, this well controlled study included the highest approved dose of hPTH (1-84) (Natpar</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;"><font style="background-color: #FFFFFF;">&#174;</font></sup><font style="background-color: #FFFFFF;">) 100 micrograms as an active control.&#8221;</font></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;"><font style="background-color: #FFFFFF;">&#8220;The data from this study suggest that our Oral PTH delivered at different frequencies, and
        with different doses, can be used effectively to customize the therapy of individual patients. For example, some patients with elevated urinary calcium might be well served with more frequent dosing three or four times daily, while patients who
        have milder disease might be adequately served by less frequent twice-a-day dosing. We as clinicians find the severity of disease is a continuum that is best treated by custom titration calcium and each drug to each patient&#8217;s needs,&#8221; stated Dr.
        Arthur Santora, Chief Medical Officer of Entera. &#8220;Both PK and PD data from this study will be very valuable in helping optimize the formulation of Oral hPTH (1-34) for hypoparathyroidism, as well as designing long-term studies of a diverse
        hypoparathyroid population.&#160; Importantly, for our ongoing dose ranging study in osteoporosis that employs a single daily dose of oral hPTH (1-34) each morning, the PK profile of the morning dose of oral hPTH (1-34) from this PK/PD study further
        supports our belief that the blood levels after a single daily morning dose of oral hPTH (1-34) may be sufficient to increase bone formation markers and BMD.&#8221;</font></div>
    <div style="text-align: justify; line-height: 1.25;"><font style="background-color: #FFFFFF;"> <br>
      </font></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">PK/PD Study Design</div>
    <div style="text-align: justify; line-height: 1.25;">The Phase 2 PK/PD Study was open-label, and employed a 2-period partial crossover design to evaluate the PK and PD profiles of two
      doses, 0.75 mg and 2.25 mg, and three regimens (BID, TID and QID) of Oral hPTH (1-34) and included subcutaneous Natpar<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> [hPTH (1-84)] 100 &#181;g once daily. The study was conducted in&#160; sixteen patients with hypoparathyroidism at the Hadassah
      Clinical Research Center in Jerusalem, Israel. Twelve patients were allocated to receive two treatments each and four patients were allocated to receive four treatments each. All patients continued to receive their usual therapy (calcium supplements
      plus alfacalcidol or calcitriol).</div>
    <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Preliminary results from Part 1 of this study, were reported by Entera Bio in a press release in November 2018. The full study data
      analyses presented at the ASBMR meeting demonstrated a positive impact of Oral PTH on three metabolic parameters - serum calcium, phosphate, and 1,25-dihydroxyvitamin D (&#8220;active&#8221; vitamin D) - in patients with hypoparathyroidism treated with oral hPTH
      (1-34) 2.25 mg QID. There was also a decrease in 24-hour urine calcium.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">The full data set is being prepared for publication in a
        leading medical journal, and the poster presentation is available on the <u>&#8220;Events&#8221;</u> section of Entera Bio website.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;"><font style="background-color: #FFFFFF;">The conclusions of the poster presentation indicate that:</font></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z502f9b6eebd846af838d5173333437a3" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">
              <div style="margin-left: 18pt; line-height: 1.25;">&#9726;</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">Oral&#160; hPTH(1-34) 2.25 mg QID for one day is associated with an increase in serum albumin-corrected calcium and 1,25(OH)<sub style="vertical-align: bottom; line-height: 1; font-size: smaller;">2</sub>D
                (1,25-dihydroxyvitamin D), a decrease in serum phosphate, and a decrease in urinary calcium in patients with hypoparathyroidism. The patients also received calcium supplements and either alfacalcidol or calcitriol.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="zb3e8162cd3d0483485ea6cac2871f079" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">
              <div style="margin-left: 18pt; line-height: 1.25;">&#9726;</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">Oral PTH produced similar biological effects to Natpara<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> 100 &#181;g QD, the highest dose of hPTH (1-84) currently indicated for use in patients with hypoparathyroidism, on serum calcium, phosphate and Vit D. Additionally, Oral hPTH (1-34) effected a decrease in
                  urinary calcium. These changes in serum PD parameters were sustained over the 24-hour period of observation from time zero.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="zf93183680d984e2b9eee1a91178a498d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">
              <div style="margin-left: 18pt; line-height: 1.25;">&#9726;</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">BID, TID and QID regimens showed a dose-dependent increase in 1,25(OH)<sub style="vertical-align: bottom; line-height: 1; font-size: smaller;">2</sub>D indicating that the long-term treatment,
                even with the less frequent regimens, may be an effective treatment option for those patients suffering from less severe hypoparathyroidism.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="zfc224681f14a44aa98fa5ab8a39a1fc1" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">
              <div style="margin-left: 18pt; line-height: 1.25;">&#9726;</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">Treatment with Oral hPTH (1-34) dosed at multiple times during the day has the potential to reduce calciuria generally
                associated with maintenance of serum calcium within the normal range using calcium supplements and calcitriol analogs alone.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="za5095f240e7c44738136fa658925fbfc" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">
              <div style="margin-left: 18pt; line-height: 1.25;">&#9726;</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">There were no treatment-emergent adverse events of hypercalcemia, as well as&#160; no treatment-emergent Serious Adverse Events
                reported in the study.</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">About Hypoparathyroidism</div>
    <div style="text-align: justify; line-height: 1.25;"><font style="background-color: #FFFFFF;">Hypoparathyroidism is a rare condition in which the body produces insufficient amounts of PTH.
        Individuals with a deficiency of PTH typically exhibit abnormally low levels of calcium in the blood, or hypocalcemia, and high levels of phosphate in the blood, or hyperphosphatemia. Hypoparathyroidism is estimated to affect approximately 77,000
        individuals in&#160;the United States. Historically, the treatments for hypoparathyroidism have been calcium supplements and active vitamin D (calcitriol or alfacalcidol). Phosphate binders and thiazide diuretics that reduce urine calcium are
        occasionally added. It is often difficult to titrate the dose of active vitamin D without producing increased urine calcium or hypercalcemia with tissue calcification during chronic use, which can result in significant costs to the healthcare
        system. Natpara&#174;, a once-daily injectable form of PTH, has been approved by the&#160;FDA&#160;and EMA for the treatment of hypocalcemia in patients with hypoparathyroidism.</font></div>
    <div style="text-align: justify; line-height: 1.25;"><font style="background-color: #FFFFFF;"> <br>
      </font></div>
    <div style="text-align: center;"><font style="background-color: rgb(255, 255, 255);">2<br>
      </font></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;"><font style="background-color: #FFFFFF;">*Natpara&#174;&#160;is the brand name used in&#160;United States&#160;for Natpar&#174;&#160;which is sold by&#160;Takeda
        in&#160;Europe. Natpar&#174;&#160;was used in this Phase 2 clinical trial.</font></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">About Entera Bio Ltd.</div>
    <div style="text-align: justify; line-height: 1.25;"><font style="background-color: #FFFFFF;">Entera Bio is a clinical-stage biopharmaceutical company focused on the development and
        commercialization of orally delivered large molecule therapeutics for use in orphan indications and other areas with significant unmet medical needs. The Company is initially applying its technology to develop an oral formulation of a human
        parathyroid hormone analog, Oral PTH (1-34), for treatment of hypoparathyroidism and osteoporosis.</font></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;"><font style="background-color: #FFFFFF;">Entera has developed a
        proprietary platform technology that enables oral delivery of biologicals and large molecule drugs, which are typically delivered via injections and or other non-oral pathways. However, oral drug delivery is the easiest method for
        self-administering medications, offers patients greater dosing flexibility, and has the highest patient acceptance and compliance rates as compared to all other routes of drug administration. The Company employs this technology for its own pipeline
        products and may enter into licensing agreements with biopharma companies for application of the technology to their proprietary compounds, such as the Amgen strategic research collaboration.&#160; For more information on&#160;Entera Bio, visit&#160;</font><font style="background-color: #FFFFFF;">www.enterabio.com</font><font style="background-color: #FFFFFF;">.</font></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Forward Looking Statements</div>
    <div style="text-align: justify; line-height: 1.25;">This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.&#160;
      Words such as "may," "should," "could," "would," "predicts," "potential," "continue," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," and similar expressions, as well as statements in future tense, often signify
      forward-looking statements.&#160;Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward-looking statements are based
      on information that the Company has when those statements are made or management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ
      materially from those expressed in or suggested by the forward-looking statements.&#160;Those risks and uncertainties, include, but are not limited to, the timing and conduct of our clinical trials, the clinical utility of our product candidates, the
      timing and likelihood of regulatory filings and approvals, our intellectual property position, and our financial position. For a discussion of these and other risks that could cause such differences and that may affect the realization of
      forward-looking statements, please refer to the "Special Note Regarding Forward-Looking Statements" and "Risk Factors" in the Company's Annual Report on Form 20-F and other filings with the Securities and Exchange Commission (SEC).&#160; Investors and
      security holders are urged to read these documents free of charge on the SEC's web site at&#160;<u>http://www.sec.gov</u>. The Company assumes no obligation to publicly
      update or revise its forward-looking statements as a result of new information, future events or otherwise.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; text-align: center;">3<br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div style="line-height: 1.25">&#160;</div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
